Growth Factor Antagonists in Prostatic Cancer: Suramin and Cytotoxic Polyamines as Potential Therapy
Prostatic Cancer is the leading site for cancer in men over 50 years of age and is the second leading cause of cancer deaths in the US (1). Clinically manifest prostatic cancer is more common in the US than in Japan while the incidence of latent cancer is similar between the two countries. The incidence of prostatic cancer of first generation males of Japanese living in the US is the same as that of US males. The implication is that life style differences are important for the progression of the disease. As prostatic cancer is refractory to most standard chemotherapeutic agents and hormone therapy is only palliative it may be that it will be easier to prevent the progression of prostatic cancer than to cure it. Consideration should be given to 3 omega unsaturated fatty acids, which are common in fish oils, as possible agents in a study of prevention of progression. The 3 omega unsaturated fatty acids have proven beneficial in the prevention of cancer and reduced the growth of prostatic cancer in nude mice (2,3). Other cultural differences in nutrition such as the use of green tea should be investigated to identify other potential anti-tumor progression factors.
KeywordsProstatic Cancer LNCaP Cell Diamine Oxidase Human Prostatic Cancer Cell Line Polyamine Synthesis
Unable to display preview. Download preview PDF.
- 1.Silverburg, E., and Lubera, J.A. Cancer Statistics, CA 39:3–22, 1989.Google Scholar
- 9.Porter, C.W. and Sufrin, J.R Interference with polyamine biosynthesis and/or function by analogs of polyamines or methionine as a potential chemotherapeutic strategy. Anticancer Res., 6:535–535, 1986.Google Scholar
- 12.Romijin, J.C., Van Steenbruge, G.J. and Schroeder, F.H. Effects of polyamine antimetabolites in the growth rate of human prostatic tumors transplantable into nude mice. Fouth int. workshop on immune deficient animals. (Karger, Basel) pp. 370, 1984.Google Scholar
- 14.Kadmon, D. and Heston, W.D.W. Manuscript in preparation.Google Scholar
- 17.Welch, M.J., Coleman, R.E., Straatman, M.G., Asberry, B.E., Primeau, J.L., Fair, W.R. and Ter-Pergossian, M.-M. C11-labeled methylated polyamine analogs: uptake in prostate and tumor in animal models. J. Nuel. Med., 18:74–78, 1977.Google Scholar
- 18.Kadmon, D., Welsh, M.J., and personal communication.Google Scholar
- 23.Scher, H., Yagoda, A., Ahmed, T., et al. Phase II trial of mitoguazone in patients with hormone resistant adenocarcinoma of the prostate. J. Clin. Oncol., 3:224–229, 1989.Google Scholar
- 26.Matuo, Y., Nishi Matsui, S., Sandberg, A.A., Issacs, J.T. and Wada, F. Heparin binding affinity of rat prostatic growth factor in normal and cancerous prostates: partial purification and characterization of rat prostatic growth factor in the Dunning tumor. Cancer Res., 47:188–192, 1987.PubMedGoogle Scholar
- 27.Mannson, P.F., Adams, P., Kan, M. and McKeehan W.L. Heparin-binding growth factor gene expression and receptor characteristics in normal rat prostate and two transplantable rat prostate tumors. Cancer Res., 49:1485–1494, 1989.Google Scholar
- 34.Myers, C.E. Presentation at MSKCC.Google Scholar